Coherus Biosciences Divests UDENYCA Business
I'm PortAI, I can summarize articles.
Coherus Biosciences has divested its UDENYCA business, marking a significant shift in its strategy by focusing on its innovative oncology pipeline and expanding LOQTORZI sales. This divestiture includes the UDENYCA, YUSIMRY, and CIMERLI franchises, now classified as discontinued operations. The latest analyst rating for Coherus Biosciences stock is a Hold with a $1.50 price target, reflecting financial challenges and bearish momentum despite some positive strategic initiatives.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments